{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-248694","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.054468+00:00","generated_at":"2026-05-30T07:19:27.782172+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development","bullets":["Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.","Net proceeds of ~$151.1M after underwriting discounts and expenses; original offering was upsized from $125M to $161M gross.","Proceeds to fund DURAVYU clinical development for wet AMD & DME, early-stage pipeline, and general corporate purposes.","Joint book-runners: J.P. Morgan, Citigroup, Guggenheim Securities; co-managers: Baird, Mizuho, Jones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-248694","json":"https://secwatch.observer/filing/0001193125-24-248694.json","markdown":"https://secwatch.observer/filing/0001193125-24-248694.md","text":"https://secwatch.observer/filing/0001193125-24-248694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312524248694/0001193125-24-248694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312524248694/d904414d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:19:27.782172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}